Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
- 15 May 1995
- journal article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 32 (2), 293-306
- https://doi.org/10.1016/0360-3016(95)00077-c
Abstract
This study was undertaken to: (a) define the prognostic significance of pretreatment serum prostate-specific antigen (PSA) levels in localized prostate cancer treated with radiation; (b) define the prognostic usefulness of postradiation PSA levels; (c) evaluate the outcome of radiation using PSA as an endpoint. Disease outcome in 707 patients with Stages T1 (205 men), T2 (256 men), T3 (239 men), and T4 (7 men), receiving definitive external radiation as sole therapy, was evaluated using univariate and multivariate techniques. At a mean follow-up of 31 months, 157 patients (22%) developed relapse or a rising PSA. Multivariate analysis revealed pretreatment PSA level to be the most significant prognostic factor, with lesser though significant contributions due to Gleason grade (2-6 vs. 7-10) and transurethral resection in T3/T4 disease. The following four prognostic groupings were defined: group I, PSA < or = 4 ng/ml, any grade; group II, 4 < PSA < or = 20, grades 2-6; group III, 4 < PSA < or = 20, grades 7-10; group IV, PSA > 20, any grade. Five-year actuarial relapse rates in these groups were: I, 12%; II, 34%; III, 40%; and IV, 81%. Posttreatment nadir PSA was an independent determinant of outcome and only patients with nadir values < 1 ng/ml fared well (5-year relapse rate 20%). Using rising PSA as an endpoint the 461 patients with T1/T2 disease had an actuarial freedom from disease rate of 70% at 5 years, which appeared to plateau, suggesting that many were cured. No plateau was evident for T3/T4 disease. Pretreatment serum PSA is the single most important predictor of disease outcome after radiation for local prostate cancer. Tumor grade has a lesser though significant prognostic role. Postirradiation nadir PSA value during the first year is a sensitive indicator of response to treatment. Only nadir values < 1 ng/ml are associated with a favorable outlook. A significant fraction of men with T1/T2 disease may be cured with radiation. There was no evidence for a cured fraction among patients with T3/T4 disease.Keywords
This publication has 33 references indexed in Scilit:
- The prognostic importance of gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancerUrology, 1994
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implicationsInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The radiation therapy oncology group 75-06 and 77-06 experienceInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Pelvic lymphadenectomy for staging clinically localized prostate cancer Indications, Complications, and Results in 217 CasesUrology, 1990
- The Incidence of Monotone Likelihood in the Cox ModelTechnometrics, 1981
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978